Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $1.78 billion. The enterprise value is $1.48 billion.
| Market Cap | 1.78B |
| Enterprise Value | 1.48B |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 70.96 million shares outstanding. The number of shares has decreased by -0.84% in one year.
| Current Share Class | 70.96M |
| Shares Outstanding | 70.96M |
| Shares Change (YoY) | -0.84% |
| Shares Change (QoQ) | -2.28% |
| Owned by Insiders (%) | 1.32% |
| Owned by Institutions (%) | 44.17% |
| Float | 65.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.02 |
| PS Ratio | 48.01 |
| Forward PS | 5.12 |
| PB Ratio | 22.32 |
| P/TBV Ratio | 26.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 39.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.32, with a Debt / Equity ratio of 0.20.
| Current Ratio | 6.32 |
| Quick Ratio | 5.86 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.96 |
Financial Efficiency
Return on equity (ROE) is -72.31% and return on invested capital (ROIC) is -97.68%.
| Return on Equity (ROE) | -72.31% |
| Return on Assets (ROA) | -24.14% |
| Return on Invested Capital (ROIC) | -97.68% |
| Return on Capital Employed (ROCE) | -44.48% |
| Weighted Average Cost of Capital (WACC) | 10.86% |
| Revenue Per Employee | $160,723 |
| Profits Per Employee | -$649,316 |
| Employee Count | 231 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.40M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +80.20% in the last 52 weeks. The beta is 1.15, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | +80.20% |
| 50-Day Moving Average | 24.03 |
| 200-Day Moving Average | 24.27 |
| Relative Strength Index (RSI) | 58.36 |
| Average Volume (20 Days) | 453,596 |
Short Selling Information
The latest short interest is 4.11 million, so 5.79% of the outstanding shares have been sold short.
| Short Interest | 4.11M |
| Short Previous Month | 4.10M |
| Short % of Shares Out | 5.79% |
| Short % of Float | 6.24% |
| Short Ratio (days to cover) | 8.42 |
Income Statement
In the last 12 months, Zymeworks had revenue of $37.13 million and -$149.99 million in losses. Loss per share was -$2.01.
| Revenue | 37.13M |
| Gross Profit | -91.58M |
| Operating Income | -155.56M |
| Pretax Income | -151.39M |
| Net Income | -149.99M |
| EBITDA | -150.65M |
| EBIT | -155.56M |
| Loss Per Share | -$2.01 |
Balance Sheet
The company has $270.70 million in cash and $16.01 million in debt, with a net cash position of $306.47 million or $4.32 per share.
| Cash & Cash Equivalents | 270.70M |
| Total Debt | 16.01M |
| Net Cash | 306.47M |
| Net Cash Per Share | $4.32 |
| Equity (Book Value) | 80.37M |
| Book Value Per Share | 1.13 |
| Working Capital | 251.15M |
Cash Flow
In the last 12 months, operating cash flow was -$119.34 million and capital expenditures -$1.21 million, giving a free cash flow of -$120.54 million.
| Operating Cash Flow | -119.34M |
| Capital Expenditures | -1.21M |
| Depreciation & Amortization | 4.91M |
| Net Borrowing | n/a |
| Free Cash Flow | -120.54M |
| FCF Per Share | -$1.70 |
Margins
| Gross Margin | -246.66% |
| Operating Margin | -418.99% |
| Pretax Margin | -407.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.84% |
| Shareholder Yield | 0.84% |
| Earnings Yield | -8.41% |
| FCF Yield | -6.76% |
Analyst Forecast
The average price target for Zymeworks is $40.33, which is 60.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.33 |
| Price Target Difference | 60.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 25.57% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of -1.58 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.58 |
| Piotroski F-Score | 1 |